Sees FY24 adjusted EBITDA (14M)-(8M) vs. ($17.7M) in 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVRO:
- Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
- NVRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Nevro price target lowered to $19 from $23 at Canaccord
- Nevro announces Carelon publication on new interventional pain management policy
- Nevro downgraded to Sector Perform from Outperform at RBC Capital
